- Home
- RHE vs TOVX Comparison
RHE vs TOVX Comparison
Compare RHE & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RHE
- TOVX
- Stock Information
- Founded
- RHE 1988
- TOVX 2001
- Country
- RHE United States
- TOVX United States
- Employees
- RHE N/A
- TOVX N/A
- Industry
- RHE Real Estate
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- RHE Real Estate
- TOVX Health Care
- Exchange
- RHE Nasdaq
- TOVX Nasdaq
- Market Cap
- RHE 2.9M
- TOVX 3.2M
- IPO Year
- RHE 2006
- TOVX 2006
- Fundamental
- Price
- RHE $2.29
- TOVX $1.48
- Analyst Decision
- RHE
- TOVX Strong Buy
- Analyst Count
- RHE 0
- TOVX 1
- Target Price
- RHE N/A
- TOVX $6.00
- AVG Volume (30 Days)
- RHE 2.2M
- TOVX 1.2M
- Earning Date
- RHE 11-19-2024
- TOVX 11-12-2024
- Dividend Yield
- RHE N/A
- TOVX N/A
- EPS Growth
- RHE N/A
- TOVX N/A
- EPS
- RHE N/A
- TOVX N/A
- Revenue
- RHE $15,753,000.00
- TOVX N/A
- Revenue This Year
- RHE N/A
- TOVX N/A
- Revenue Next Year
- RHE N/A
- TOVX N/A
- P/E Ratio
- RHE N/A
- TOVX N/A
- Revenue Growth
- RHE N/A
- TOVX N/A
- 52 Week Low
- RHE $1.13
- TOVX $1.14
- 52 Week High
- RHE $6.80
- TOVX $17.00
- Technical
- Relative Strength Index (RSI)
- RHE 57.17
- TOVX 49.48
- Support Level
- RHE $1.78
- TOVX $1.42
- Resistance Level
- RHE $2.58
- TOVX $2.03
- Average True Range (ATR)
- RHE 0.53
- TOVX 0.17
- MACD
- RHE 0.02
- TOVX -0.01
- Stochastic Oscillator
- RHE 16.33
- TOVX 12.70
About RHE Regional Health Properties Inc.
Regional Health Properties Inc is a self-managed healthcare real estate investment company that invests in real estate purposed for senior living and long-term healthcare through facility lease and sub-lease transactions. It has two reportable segments real estate segment and the healthcare services segment. It derives the majority of its revenue from the healthcare services segment. Its portfolio of properties is diversified across various states, with concentrations in Georgia and Ohio.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.